NEW YORK and MAINZ, GERMANY, DECEMBER 9, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced...
Intranasal administration of Ampligen demonstrated to be well-tolerated Based on data generated to date, Ampligen could have potential as a...
Data Presented at ESMO Immuno-Oncology CongressSOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT),...
Continued Positive Safety Data for OCU400 Established High Dose as the Maximum Tolerable Dose in Current OCU400 Clinical Trial MALVERN,...
Program-Related Investment and Grant from the Bill & Melinda Gates Foundation to advance RIGImmune’s RNA therapeutics platform for influenza and...
Modified mRNA sequence of the Spike protein prevents cleavage of the expressed protein, which may potentially result in a cleaner...
LOS ANGELES, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused...
CINCINNATI, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”) a...
Eascra partners with University of Connecticut and Axiom Space to develop in-space manufacturing processesBoston, Dec. 06, 2022 (GLOBE NEWSWIRE) --...
Professor Dr. med. Matthias Dobbelstein Professor Dr. med. Matthias DobbelsteinJerusalem, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals...
Vaxxinity’s next-generation COVID-19 booster candidate UB-612 achieves primary and key secondary immunogenicity endpoints in a pivotal head-to-head heterologous booster trial...
THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.12 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE...
CINCINNATI, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today...
LOWELL, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences...
Initial CD388 clinical data expected in the first half of 2023SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics,...
Roivant to develop PF-06480605 (now RVT-3101), a potential first in class, fully human monoclonal antibody that blocks tumor necrosis factor-like...
Funding and support provided by Bill & Melinda Gates Foundation Study will focus on determining the ability of oral vaccine...
Predicts AI and Machine Learning, Diversity and Medical Affairs will Transform Biopharma Product DevelopmentMORRISVILLE, N.C., Dec. 01, 2022 (GLOBE NEWSWIRE) --...
Global Study to Evaluate Bemnifosbuvir as Monotherapy and in Combination in Non-Hospitalized Patients at High Risk of Disease Progression, Regardless...
Hamsters infected with SARS-COV-2 and then treated with inhaled anti-COVID-19 NanoAbs demonstrated significantly less severe illness and faster recovery in...